Please login to the form below

Not currently logged in
Email:
Password:

selumetinib

This page shows the latest selumetinib news and features for those working in and with pharma, biotech and healthcare.

AZ nabs US approval for new leukaemia drug Lumoxiti

AZ nabs US approval for new leukaemia drug Lumoxiti

It has assumed greater importance for the targeted pipeline – which sits alongside AZ’s immuno-oncology R&D – since MEK Inhibitor selumetinib failed late-stage trials in thyroid cancer and lung

Latest news

More from news
Approximately 3 fully matching, plus 9 partially matching documents found.

Latest Intelligence

  • Interview: AstraZeneca's Susan Galbraith Interview: AstraZeneca's Susan Galbraith

    But now hopes are high for two late-stage drugs: olaparib and selumetinib. ... With selumetinib you've now got that plus another 20-25 per cent of NSCLC cases - people with the KRAS mutation.”.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Apex.co.uk Conferences, Events and Exhibition Stands

Apex.co.uk is one of the UK’s leading event and exhibition agencies, specialising in healthcare. We understand your communication goals, whether...

Latest intelligence

The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....
Escaping the spin cycle of sub-optimal launch
...

Infographics